FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Physical medicine and rehabilitation clinics of North America2016; 27(4); 893-908; doi: 10.1016/j.pmr.2016.06.003

Autologous Conditioned Serum.

Abstract: Autologous conditioned serum was developed in the mid 1990s as an expeditious, practical, and relatively inexpensive means of generating the interleukin-1 receptor antagonist, a naturally occurring inhibitor of the cytokine interleukin-1. The latter is thought to be an important mediator of inflammation, pain, and tissue destruction in musculoskeletal conditions. ACS has been widely and successfully used in the local treatment of human and equine osteoarthritis and radicular compression; it has also shown promise in treating tendinopathies, muscle injuries, and tunnel widening after reconstruction of the anterior cruciate ligament. Experience suggests that autologous conditioned serum is safe and effective.
Copyright © 2016 Elsevier Inc. All rights reserved.
Get Full Text
Publication Date: 2016-10-30 PubMed ID: 27788906DOI: 10.1016/j.pmr.2016.06.003Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article is about Autologous Conditioned Serum (ACS), a developement from the mid-1990s, which serves as a cost-effective method for the production of interleukin-1 receptor antagonist. The research explores its utility in treating musculoskeletal conditions, due to its role in mediating inflammation, pain, and tissue damage.

Development and Utilization of Autologous Conditioned Serum

  • The research explains the development of Autologous conditioned serum (ACS) in the mid-1990s. ACS is a result of a patient’s blood, conditioned in a specialized way to increase the levels of certain anti-inflammatory proteins and growth factors, which include the Interleukin-1 receptor antagonist (IL-1Ra).
  • Interleukin-1 receptor antagonist is a natural inhibitor of the cytokine interleukin-1, which plays a crucial role in inflammation, pain, and tissue destruction in musculoskeletal conditions. With ACS, ample amounts of this inhibitor can be produced in a cost-effective, easy, and quicker way.

Application of Autologous Conditioned Serum

  • The research reveals that ACS demonstrated a high level of utility in human and equine osteoarthritis and radicular compression. It has been used mainly in the local treatment of these medical conditions.
  • Additionally, ACS has also proven its worth in treating tendinopathies and muscle injuries. It also shows promising results in narrow tunneling, which is a common occurrence after the reconstruction of the anterior cruciate ligament.

Safety and Effectiveness of Autologous Conditioned Serum

  • The research highlights that the use of ACS in treatments is generally viewed as safe and effective. The experience and results from its utility have suggested its safety and efficacy, which warrants further investigations and applications in the medical field.

Cite This Article

APA
Evans CH, Chevalier X, Wehling P. (2016). Autologous Conditioned Serum. Phys Med Rehabil Clin N Am, 27(4), 893-908. https://doi.org/10.1016/j.pmr.2016.06.003

Publication

Physical medicine and rehabilitation clinics of North America
ISSN: 1558-1381
NlmUniqueID: 9102787
Country: United States
Language: English
Volume: 27
Issue: 4
Pages: 893-908
PII: S1047-9651(16)30044-4

Researcher Affiliations

Evans, Christopher H
  • Rehabilitation Medicine Research Center, Mayo Clinic, 200, First Street Southwest, Rochester, MN 55905, USA. Electronic address: Evans.christopher@mayo.edu.
Chevalier, Xavier
  • Department of Rheumatology, Hopital Henri Mondor, UPEC Paris XII University, Bd De latter de Tassigny, Creteil 94010, France.
Wehling, Peter
  • Orthogen AG, Ernst-Schneider-Platz 1, Düsseldorf 40212, Germany.

MeSH Terms

  • Animals
  • Biological Therapy
  • Horses
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use
  • Interleukin-1 / therapeutic use
  • Muscular Diseases / therapy
  • Pain
  • Serum / immunology

Citations

This article has been cited 25 times.
  1. Saraf A, Hussain A, Bishnoi S, Habib H, Garg A. Serial intraarticular injections of growth factor concentrate in knee osteoarthritis: A placebo controlled randomized study. J Orthop 2023 Mar;37:46-52.
    doi: 10.1016/j.jor.2023.02.006pubmed: 36974096google scholar: lookup
  2. Ippolito M, Spurio G, Compagno V, Rizzo A, Di Simone M, Corsale AM, Mazzola G, Giarratano A, Meraviglia S, Cortegiani A, Alongi A. Autologous conditioned serum for chronic pain in patients with osteoarthritis: A feasibility observational study. Br J Pain 2023 Feb;17(1):103-111.
    doi: 10.1177/20494637221134169pubmed: 36815072google scholar: lookup
  3. Vitali M, Ometti M, Pironti P, Salvato D, Sandrucci A, Leone O, Salini V. Clinical and functional evaluation of bone marrow aspirate concentrate vs autologous conditioned serum in the treatment of knee osteoarthritis. Acta Biomed 2022 Oct 26;93(5):e2022222.
    doi: 10.23750/abm.v93i5.12845pubmed: 36300237google scholar: lookup
  4. Karsmarski OP, Hawthorne BC, Cusano A, LeVasseur MR, Wellington IJ, McCarthy MB, Cote MP, Mazzocca AD. Activated Serum Increases In Vitro Cellular Proliferation and Growth Factor Expression of Musculoskeletal Cells. J Clin Med 2022 Jun 15;11(12).
    doi: 10.3390/jcm11123442pubmed: 35743510google scholar: lookup
  5. Coşkun HS, Yurtbay A, Say F. Platelet Rich Plasma Versus Autologous Conditioned Serum in Osteoarthritis of the Knee: Clinical Results of a Five-Year Retrospective Study. Cureus 2022 Apr;14(4):e24500.
    doi: 10.7759/cureus.24500pubmed: 35651374google scholar: lookup
  6. Aghamohammadi D, Sharifi S, Shakouri SK, Eslampour Y, Dolatkhah N. Autologous conditioned serum (Orthokine) injection for treatment of classical trigeminal neuralgia: results of a single-center case series. J Med Case Rep 2022 May 8;16(1):183.
    doi: 10.1186/s13256-022-03393-9pubmed: 35526052google scholar: lookup
  7. Raeissadat SA, Rayegani SM, Sohrabi MR, Jafarian N, Bahrami MN. Effectiveness of intra-articular autologous-conditioned serum injection in knee osteoarthritis: a meta-analysis study. Future Sci OA 2021 Oct;7(9):FSO759.
    doi: 10.2144/fsoa-2021-0069pubmed: 34737891google scholar: lookup
  8. Karjalainen TV, Silagy M, O'Bryan E, Johnston RV, Cyril S, Buchbinder R. Autologous blood and platelet-rich plasma injection therapy for lateral elbow pain. Cochrane Database Syst Rev 2021 Sep 30;9(9):CD010951.
    doi: 10.1002/14651858.CD010951.pub2pubmed: 34590307google scholar: lookup
  9. Camargo Garbin L, Morris MJ. A Comparative Review of Autologous Conditioned Serum and Autologous Protein Solution for Treatment of Osteoarthritis in Horses. Front Vet Sci 2021;8:602978.
    doi: 10.3389/fvets.2021.602978pubmed: 33681323google scholar: lookup
  10. Otahal A, Kramer K, Kuten-Pella O, Weiss R, Stotter C, Lacza Z, Weber V, Nehrer S, De Luna A. Characterization and Chondroprotective Effects of Extracellular Vesicles From Plasma- and Serum-Based Autologous Blood-Derived Products for Osteoarthritis Therapy. Front Bioeng Biotechnol 2020;8:584050.
    doi: 10.3389/fbioe.2020.584050pubmed: 33102466google scholar: lookup
  11. Genç E, Yüksel S, Çağlar A, Beytemur O, Güleç MA. Comparison on effects of platelet-rich plasma versus autologous conditioned serum on Achilles tendon healing in a rat model. Acta Orthop Traumatol Turc 2020 Jul;54(4):438-444.
    doi: 10.5152/j.aott.2020.18498pubmed: 32812877google scholar: lookup
  12. Angadi DS, Macdonald H, Atwal N. Autologous cell-free serum preparations in the management of knee osteoarthritis: what is the current clinical evidence?. Knee Surg Relat Res 2020 Mar 23;32(1):16.
    doi: 10.1186/s43019-020-00036-5pubmed: 32660628google scholar: lookup
  13. Vitali M, Ometti M, Drossinos A, Pironti P, Santoleri L, Salini V. Autologous conditioned serum: clinical and functional results using a novel disease modifying agent for the management of knee osteoarthritis. J Drug Assess 2020;9(1):43-51.
    doi: 10.1080/21556660.2020.1734009pubmed: 32284907google scholar: lookup
  14. Buchheit T, Huh Y, Maixner W, Cheng J, Ji RR. Neuroimmune modulation of pain and regenerative pain medicine. J Clin Invest 2020 May 1;130(5):2164-2176.
    doi: 10.1172/JCI134439pubmed: 32250346google scholar: lookup
  15. Dehghani B, Rodeo S. Cell Therapy-a Basic Science Primer for the Sports Medicine Clinician. Curr Rev Musculoskelet Med 2019 Dec;12(4):436-445.
    doi: 10.1007/s12178-019-09578-ypubmed: 31680217google scholar: lookup
  16. Blázquez R, Sánchez-Margallo FM, Reinecke J, Álvarez V, López E, Marinaro F, Casado JG. Conditioned Serum Enhances the Chondrogenic and Immunomodulatory Behavior of Mesenchymal Stem Cells. Front Pharmacol 2019;10:699.
    doi: 10.3389/fphar.2019.00699pubmed: 31316380google scholar: lookup
  17. Linardi RL, Dodson ME, Moss KL, King WJ, Ortved KF. The Effect of Autologous Protein Solution on the Inflammatory Cascade in Stimulated Equine Chondrocytes. Front Vet Sci 2019;6:64.
    doi: 10.3389/fvets.2019.00064pubmed: 30895181google scholar: lookup
  18. Huang D, Liu YQ, Liang LS, Lin XW, Song T, Zhuang ZG, Wang SL, Bao HG, Wang L, Zhang XW, Cheng ZG, Duan BL, Qiu WD, Xiong YC, Liu JF. The Diagnosis and Therapy of Degenerative Knee Joint Disease: Expert Consensus from the Chinese Pain Medicine Panel. Pain Res Manag 2018;2018:2010129.
    doi: 10.1155/2018/2010129pubmed: 30651899google scholar: lookup
  19. Strümper R. Intra-Articular Injections of Autologous Conditioned Serum to Treat Pain from Meniscal Lesions. Sports Med Int Open 2017 Oct;1(6):E200-E205.
    doi: 10.1055/s-0043-118625pubmed: 30539108google scholar: lookup
  20. Genç E, Beytemur O, Yuksel S, Eren Y, Çağlar A, Küçükyıldırım BO, Güleç MA. Investigation of the biomechanical and histopathological effects of autologous conditioned serum on healing of Achilles tendon. Acta Orthop Traumatol Turc 2018 May;52(3):226-231.
    doi: 10.1016/j.aott.2018.01.005pubmed: 29454565google scholar: lookup
  21. Miller C, Bedi A. Regenerative Medicine: The Next Generation of Autologous Blood Formulations. HSS J 2025 Oct 4;:15563316251367029.
    doi: 10.1177/15563316251367029pubmed: 41054601google scholar: lookup
  22. Zamani M, Kaviani S, Yousefi M, Abroun S, Hojjat-Farsangi M, Pourabbas B. Conditioned plasma promotes full-thickness skin defect healing in a rat model. Regen Ther 2025 Dec;30:629-640.
    doi: 10.1016/j.reth.2025.08.003pubmed: 40896180google scholar: lookup
  23. Rajkovic CJ, Merckling ML, Lee AW, Subah G, Malhotra A, Thomas ZD, Zeller SL, Wainwright JV, Kinon MD. Conservative management of spinal pathology with autologous conditioned serum: A systematic review of the literature. World J Orthop 2024 Sep 18;15(9):870-881.
    doi: 10.5312/wjo.v15.i9.870pubmed: 39318497google scholar: lookup
  24. Bahari Golamkaboudi A, Vojoudi E, Babaeian Roshani K, Porouhan P, Houshangi D, Barabadi Z. Current Non-Surgical Curative Regenerative Therapies for Knee Osteoarthritis. Stem Cell Rev Rep 2024 Nov;20(8):2104-2123.
    doi: 10.1007/s12015-024-10768-6pubmed: 39145857google scholar: lookup
  25. Buchheit T, Huh Y, Breglio A, Bang S, Xu J, Matsuoka Y, Guo R, Bortsov A, Reinecke J, Wehling P, Jun Huang T, Ji RR. Intrathecal administration of conditioned serum from different species resolves Chemotherapy-Induced neuropathic pain in mice via secretory exosomes. Brain Behav Immun 2023 Jul;111:298-311.
    doi: 10.1016/j.bbi.2023.04.013pubmed: 37150265google scholar: lookup
Subscribe to our newsletter
Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.